NRAS mutations were also prone to normal cytogenetics and were significantly more frequent in MDS-AML, implying they might increase the risk of leukemic transformation in cytogenetically normal MDS [20] and have diagnostic value for MDS-AML. This evidence concerns the gene NRAS and myelodysplastic syndrome.